<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745586</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00845</org_study_id>
    <nct_id>NCT03745586</nct_id>
  </id_info>
  <brief_title>Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab</brief_title>
  <acronym>GUSTO</acronym>
  <official_title>Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant&#xD;
      cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg&#xD;
      bodyweight i.v. in 4-weekly intervals and 162mg weekly s.c., respectively). In both trials&#xD;
      glucocorticoids (GC) were initially administrated at medium to high doses with subsequent&#xD;
      rapid reduction and discontinuation over 24 weeks. In case of relapse, GC doses were&#xD;
      re-increased.&#xD;
&#xD;
      The results of both studies suggest that GC could be reduced more rapidly. This would further&#xD;
      reduce GC-induced adverse effects.&#xD;
&#xD;
      Thus, the investigators propose to perform an open label single arm study to assess the&#xD;
      efficacy of ultra-short co-medication with GC, using Simon's minimax two-stage design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients achieving remission within 31 days and without relapse until week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>Week 24 and week 52</time_frame>
    <description>Proportion of patients with complete relapse-free remission of disease at week 24 and at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Time to first relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>All study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Day0-day2: methylprednisolone 500mg i.v.</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly onset Giant Cell Arteritis (GCA) with diagnosis of GCA within 4&#xD;
             weeks before screening visit, satisfying ACR criteria and a CRP &gt; 25 mg/L AND biopsy&#xD;
             proven GCA (according to ACR criteria) OR a large vessel vasculitis assessed by MR&#xD;
             Angiography (MRA) or PET/CT (PET).&#xD;
&#xD;
          2. Previous treatment with GC for a maximum of 10 days since diagnosis of GCA at a&#xD;
             maximal dose of 60 mg/day of prednisone or equivalent.&#xD;
&#xD;
          3. Patient's written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rheumatic diseases (except for CPPD/chondrocalcinosis) other than GCA or polymyalgia&#xD;
             rheumatica (i.e., RA, autoimmune connectivitides, other systemic vasculitides, a.o.)&#xD;
&#xD;
          2. Chronic use of systemic CS with inability, in the opinion of the investigator, to&#xD;
             withdraw CS treatment at day 4 according to protocol&#xD;
&#xD;
          3. Evidence of significant and/or uncontrolled concomitant disease such as, but not&#xD;
             limited to, cardiovascular disease, nervous system, pulmonary, renal, hepatic,&#xD;
             endocrine (in particular diabetes mellitus) or gastrointestinal disorders (including&#xD;
             previous complicated diverticulitis) which, in the investigator's opinion, would&#xD;
             preclude patient participation or impact the benefit-risk ratio&#xD;
&#xD;
          4. Any condition or general state of health which, in the Investigator's opinion, would&#xD;
             preclude participation in the study&#xD;
&#xD;
          5. Actual or recent myocardial infarction (within the last 3 months before screening&#xD;
             visit)&#xD;
&#xD;
          6. Significant cardiac disease (NYHA Class III and IV), known severe chronic obstructive&#xD;
             pulmonary disease (COPD) (FEV1 &lt; 50% predicted or Functional dyspnea &gt; Grade 3 on the&#xD;
             MRC Dyspnea Scale) or other significant pulmonary disease&#xD;
&#xD;
          7. Uncontrolled disease (such as asthma, psoriasis or inflammatory bowel disease) where&#xD;
             flares are commonly treated with oral or injectable corticosteroids&#xD;
&#xD;
          8. Known active infection of any kind, or any major episode of infection requiring&#xD;
             hospitalization or treatment with i.v. anti-infectives within 4 weeks of baseline or&#xD;
             completion of oral anti-infectives within 2 weeks before screening visit&#xD;
&#xD;
          9. History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within&#xD;
             52 weeks before screening visit&#xD;
&#xD;
         10. Any surgical procedure, including bone/joint surgery within 8 weeks prior before&#xD;
             screening visit or planned within the duration of the study&#xD;
&#xD;
         11. History of serious recurrent or chronic infection (for screening for a chest infection&#xD;
             a chest radiograph will be performed at screening if not performed within 12 weeks&#xD;
             before screening visit&#xD;
&#xD;
         12. Lack of peripheral venous access&#xD;
&#xD;
         13. Body weight &gt; 150 kg or BMI &gt; 35&#xD;
&#xD;
         14. Previous treatment with tocilizumab or any other biological agent within last 6 months&#xD;
             before screening visit; Rituximab within 12 months before screening visit&#xD;
&#xD;
         15. Treatment with any investigational agent within 28 days of screening visit or 5&#xD;
             half-lives of the investigational drug (whichever is the longer)&#xD;
&#xD;
         16. History of severe allergic or anaphylactic reaction to any biologic agent or known&#xD;
             hypersensitivity to any component of tocilizumab&#xD;
&#xD;
         17. Receipt of any vaccine within 28 days prior to screening visit (a patient's&#xD;
             vaccination record and need for immunization prior to receiving tocilizumab/placebo&#xD;
             must be carefully investigated)&#xD;
&#xD;
         18. Positive tests for hepatitis B surface antigen (HBsAg) or hepatitis C serology&#xD;
&#xD;
         19. Positive Quantiferon-TB test for latent Tb without subsequent INH prophylaxis&#xD;
&#xD;
         20. Patients with active Tb which had to be treated for Tb within 2 years before the&#xD;
             screening visit&#xD;
&#xD;
         21. Absolute neutrophil count (ANC) &lt; 2.0 x 103/L, white blood cells &lt; 2.5 x 103/L,&#xD;
             platelet count &lt; 100,000/L&#xD;
&#xD;
         22. Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
         23. Concentrations of serum IgG and/or IgM below 5.0 mg/mL and 0.40 mg/mL, respectively&#xD;
&#xD;
         24. Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
         25. Alanine aminotransferase (ALT) or aspartate amino-transferase (AST) &gt; 1.5 times the&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
         26. Total bilirubin &gt; 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
         27. Triglycerides &gt; 400 mmol/dL (non-fasted) or &gt; 250 mmol/dL (fasted) at screening&#xD;
&#xD;
         28. Premenopausal status and nursing (definition of postmenopausal status: Female&#xD;
             participants who are surgically sterilised / hysterectomised or post-menopausal for&#xD;
             longer than 2 years are not considered as being of child-bearing potential)&#xD;
&#xD;
         29. Technical implants such as cardiac pacemakers (for MR-angiogram)&#xD;
&#xD;
         30. Claustrophobia (for MR-angiogram)&#xD;
&#xD;
         31. Known allergy against the contrast media (Multihance® or Dotarem® as alternative)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Villiger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

